AZD0095 is a selective and orally active MCT4 inhibitor ( IC 50 : 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib In Vitro AZD0095 (0-50 µM) inhibits cell proliferation in NCI-H358 cells (high expression of MCT4), with an IC 50 of 26 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo AZD0095 (100 mg/kg, p.o. bid) together with Cediranib (3 mg/kg, p.o.) reduces tumor growth in a murine NCI-H358 xenograft . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Murine NCI-H358 xenograft Dosage: 100 mg/kg together with Cediranib (3 mg/kg) Administration: Oral administration (p.o.) Result: Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone. Form:Solid IC50& Target:MCT4 1.3 nM (IC 50 )